Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Keith Kaye

General ID · RU

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View

Dr. Robert Schooley

General ID · UCSD

View

Dr. Priya Nori

General ID · MMC

View

Dr. Jan Patterson

General ID · UTHSCSA

View

Dr. Kavita Bhavan

General ID · Dallas County Hospital District

View

Dr. John Goldman

General ID · UPMC Central PA

View

Dr. Gonzalo Bearman

General ID · Medical College of Virginia

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.

    Feb 25, 2026DOI: 10.1093/cid/ciae648Journal ArticleCID

    Written by: Julia L MarcusAndrea WeddleColleen F KelleyAllison AgwuSheila MontalvoElizabeth ShermanTara VijayanJose GutierrezMatthew D HickeySamantha E DilworthDouglas KrakowerTeaniese L DavisLauren F CollinsMoira C McNultyJonathan A ColasantiKaterina A Christopoulos

    Find these authors on Roon

    TV
    Dr. Tara Vijayan
    General ID · UCLA

    SURVEY DESCRIPTION AND RESULTS

    In collaboration with academic researchers, HIVMA leadership developed a brief survey to identify barriers to and facilitators of implementation of LAIs for HIV treatment and prevention, specifically CAB/RPV-LA and CAB-LA, at US clinical sites. Eligibility criteria were being a healthcare provider working in HIV prevention or treatment in a US outpatient setting, including prescribers and clinical and nonclinical support staff. Respondents were asked about characteristics of their main clinical practice setting and to select and rank potential barriers to CAB/RPV-LA and CAB-LA implementation, with 5 ordinal response options for each item (“not a barrier,” “small barrier,” “somewhat of a barrier,” “big barrier,” and “very big barrier”). Respondents were also invited to share experiences with implementation of CAB/RPV-LA and CAB-LA in free-text comments.For analysis, we removed respondents practicing outside the US, missing data on region of practice, or not practicing in an outpatient setting, as well as those who left all questions blank after the screening question. For the remaining respondents, we assigned scores of 30, 20, and 10 to respondents' “biggest,” “second biggest,” and “third biggest” barriers, respectively. We computed the mean of each barrier's score to rank barriers overall and by characteristics of the respondents' clinical practice settings, including practice type, region, and whether it was in a Medicaid expansion state (41 of 51 states/jurisdictions, including Washington, District of Columbia). We also stratified by whether the respondents practiced in clinical settings that received Ryan White HIV/AIDS Program funding, which is provided to public and nonprofit organizations that serve low-income, uninsured, and other underserved people with HIV. After dichotomizing response options (“not a barrier” and “small barrier” vs “somewhat of a barrier,” “big barrier,” and “very big barrier”), we used Firth's bias-corrected logistic regression to compute unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) to identify characteristics of the respondents' clinical practice settings associated with each potential barrier.The survey was distributed by email during September through November 2023, yielding a convenience sample of 184 respondents. After exclusions for missing data, 122 individuals were included in the analysis. Most respondents had completed their training >5 years prior to the survey (83%) and reported currently practicing at academic medical centers (52%), in urban environments (75%), and in clinical settings that received Ryan White funding (78%). Approximately half of respondents practiced at sites in the South (48%), and most were in Medicaid expansion states (71%). Most respondents (76%) practiced at sites that prescribed both CAB/RPV-LA and CAB-LA, 19% at sites that prescribed only CAB/RPV-LA, and 1% at sites that prescribed only CAB-LA; the remaining 4% indicated that their site prescribed CAB/RPV-LA but not whether their site prescribed CAB-LA. Of respondents practicing at sites that prescribed CAB/RPV-LA, approximately half (46%) reported that their site prescribed the medication to patients without viral suppression on oral ART.
    Ranked barriers to CAB/RPV-LA and CAB-LA implementation are shown in Figure 1. The primary barrier domains are described below, along with policy recommendations to address each set of barriers. The policy recommendations are also summarized in Table 1.
    Ranked barriers to implementation of long-acting injectables for HIV treatment and prevention among HIV providers. Abbreviations: CAB-LA, long-acting cabotegravir; CAB/RPV-LA, long-acting cabotegravir/rilpivirine; HIV, human immunodeficiency virus; PrEP, preexposure prophylaxis.
    Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment
    Health insurers should streamline prior authorization approval and eliminate reapproval processes for LAIs for HIV treatment and prevention and work with providers to ensure these processes are transparent, rapid, and easy to follow to increase access to LAIs and reduce administrative costs and delays.
    Health insurers should offer the flexibility for LAIs for HIV treatment and prevention to be covered under either their pharmacy or medical benefit to facilitate access regardless of the size or type of clinic or practice setting.
    Congress should increase funding for the Ryan White HIV/AIDS Program and the Community Health Center Program to keep pace with increased healthcare costs and increased demand for services while ensuring access to LAIs for HIV treatment and prevention for populations that could benefit from them.
    Congress should fund the Bio-Preparedness Workforce Pilot Program that would incentivize working in Ryan White HIV/AIDS Program–funded clinics in addition to other federally funded clinics and medically underserved areas by offering loan repayment for providing infectious diseases and HIV care and treatment.
    Congress should pass national PrEP program legislation to support the infrastructure necessary to expand PrEP and other HIV prevention services to people who are uninsured or underinsured.
    Drug manufacturers should consider the importance of equitable access when setting the wholesale acquisition cost of LAI products for HIV treatment and prevention.
    Drug manufacturers should allow access to LAI products for HIV treatment and prevention outside of specialty pharmacies.
    Drug manufacturers should offer a public health price for LAI products for HIV treatment and prevention to facilitate access to these medications through public programs and health departments.
    Congress should pass legislation to close the Medicaid coverage gap in the 10 states that have not expanded Medicaid.
    Centers for Medicare and Medicaid Services and State Insurance Commissioners should fully enforce the Affordable Care Act's requirement of coverage of preventive services without cost sharing, which includes PrEP.
    States should fund PrEP drug assistance programs.
    Abbreviations: HIV, human immunodeficiency virus; LAI, long-acting injectable; PrEP, preexposure prophylaxis.
    The greatest perceived barriers to implementation of LAIs for HIV treatment and prevention were health insurance processes, specifically (1) prior authorization approval and appeals, including reverification of eligibility for continued coverage, and (2) coverage of the medications as a medical rather than a pharmacy benefit, which requires clinics to make upfront investments to cover the cost of LAIs and establish new and more complex processes for medication approval and delivery, including potential administration in infusion suites [33]. For CAB/RPV-LA, providers practicing in Ryan White–funded clinics had higher odds of selecting “medication coverage as a medical benefit” as a barrier compared with those practicing in settings not receiving Ryan White funding (OR, 3.51 [95% CI, 1.32–9.30]).
    In free-text responses, providers identified specific implementation hurdles related to prior authorization processes and medication coverage. One provider mentioned confusion related to each insurer having different medication coverage and approval processes, and another provider referenced the long duration of the approval process, which they noted could take up to 8 weeks. Providers' responses indicated that approval processes were an obstacle for LAI medication initiation and throughout medication use, with some insurers requiring reapproval to maintain coverage. Multiple respondents indicated that providers need training on the complex acquisition, prior authorization, and reimbursement landscape to facilitate implementation of LAIs.
    To address these insurance-related barriers to LAI implementation, we urge health insurers to:
    Streamline prior authorization approval and eliminate reapproval processes for LAIs for HIV treatment and prevention and work with providers to ensure these processes are transparent, rapid, and easy to follow to increase access to LAIs and reduce administrative costs and delays.
    Offer the flexibility for LAIs for HIV treatment and prevention to be covered under either pharmacy or medical benefits to facilitate access regardless of the size or type of clinic or practice setting.
    Other important barriers to LAI implementation were the need for additional staffing for injection visits and the need for additional administrative support—for example, for tracking injections, supporting reimbursement processes, and managing inventory. For CAB/RPV-LA, respondents practicing in Ryan White–funded settings had significantly higher odds of endorsing “need for additional staff” as a barrier to implementation than those practicing in settings that did not receive Ryan White funding (OR, 2.57 [95% CI, 1.06–6.27]). For CAB-LA, respondents practicing in non–Medicaid expansion states had significantly higher odds of endorsing “need for additional staff” (OR, 3.03 [95% CI, 1.10–9.10]) and “need for additional administrative support” (OR, 4.76 [95% CI, 1.27–25.00]) as barriers to implementation compared with those practicing in states that have expanded Medicaid.
    In free-text responses, providers emphasized the far higher administrative burden associated with delivery of LAIs compared with oral regimens, with one stating that the process was as challenging as delivering cancer chemotherapy. Respondents noted the lack of staff to support approval and reimbursement processes, injection visits, and follow-up with patients, as well as a lack of other needed resources (eg, physical space), as barriers to LAI implementation. Facilitators that mitigated the need for administrative support included using spreadsheets and integrating program eligibility review and tracking into electronic health records.
    To address the need for staffing and administrative support at a policy level, we recommend that:
    Congress increase funding for the Ryan White HIV/AIDS Program and the Community Health Center Program to keep pace with increased healthcare costs and increased demand for services while ensuring access to LAIs for HIV treatment and prevention for populations that could benefit from them.
    Congress fund the Bio-Preparedness Workforce Pilot Program that would incentivize working in Ryan White HIV/AIDS Program–funded clinics in addition to other federally funded clinics and medically underserved areas by offering loan repayment for providing infectious diseases and HIV care and treatment.
    Congress pass national PrEP program legislation to support the infrastructure necessary to expand PrEP and other HIV prevention services to people who are uninsured or underinsured [34, 35].
    Providers identified issues related to drug acquisition, particularly the requirement to use designated specialty pharmacies, as a barrier to implementing LAIs for both HIV treatment and prevention. Respondents indicated that policy changes with respect to specialty pharmacy requirements would be a potential facilitator of LAI implementation, specifically policies to allow access to LAI products outside of specialty pharmacies or allow use of any specialty pharmacy regardless of health insurance. One provider stated that the designation of their hospital pharmacy as a specialty pharmacy meant they could supply LAIs for treatment and prevention for most users, a facilitator they identified as key to successful implementation at their site.
    Many of the barriers to LAI implementation described herein are driven by the high prices of brand-name HIV medications. These drugs are expensive and health insurers deploy utilization management tools, such as prior authorization or not covering them at all, to control their HIV drug expenditures [36, 37]. For HIV treatment, the average wholesale price for CAB/RPV-LA is $7601 every other month for people with HIV who receive a bimonthly injection or $5067 every month for people with HIV who receive monthly injections [38, 39]. Although the average wholesale price of bimonthly CAB/RPV-LA is comparable to other widely prescribed oral ART regimens, health insurers also place restrictions on these oral HIV therapies. A higher bar has been set for the value proposition of injectable PrEP, as the average wholesale price for CAB-LA is $4440 per month while generic oral PrEP medications are available for less than $1 per day [40].
    To address barriers related to drug acquisition and costs, we recommend that drug manufacturers:
    Consider the importance of equitable access when setting the wholesale acquisition cost of LAI products for HIV treatment and prevention.
    Allow access to LAI products for HIV treatment and prevention outside of specialty pharmacies.
    Offer a public health price for LAI products for HIV treatment and prevention to facilitate access to these medications through public programs and health departments [41].
    Providers endorsed gaps in access for uninsured individuals who could benefit from LAIs for HIV treatment and prevention as an implementation barrier. For LAIs for prevention, the lack of state-funded PrEP assistance programs to cover medication costs for uninsured individuals was identified as a major barrier to implementation. For CAB-LA, the odds of endorsing “lack of a state-funded PrEP assistance program” as a barrier were significantly lower for providers practicing in Medicaid expansion states compared with those practicing in non–Medicaid expansion states (OR, 0.29 [95% CI, .07–.96]) and significantly higher for providers practicing in the South compared with those practicing in the Northeast (OR, 6.63 [95% CI, 1.91–25.64]). Not having LAIs for treatment on AIDS Drug Assistance Program formularies was also identified as a salient barrier. As of 1 January 2024, 7 states excluded CAB/RPV-LA from their AIDS Drug Assistance Program formularies (Colorado, Kentucky, Louisiana, Missouri, Oklahoma, South Dakota, and Texas) [42]. In free-text responses, providers reiterated the importance of closing gaps in access to LAIs for uninsured individuals and the need for policies and programs to support LAI access for this population.
    To address barriers related to LAI access for uninsured individuals, we recommend that:
    Congress pass legislation to close the Medicaid coverage gap in the 10 states that have not expanded Medicaid.
    Centers for Medicare and Medicaid Services and State Insurance Commissioners fully enforce the Affordable Care Act's requirement of coverage of preventive services without cost sharing, which includes PrEP.
    States fund state PrEP Drug Assistance Programs [43].

    CONCLUSIONS

    Long-acting modalities have been hailed as a potential game changer for HIV treatment and prevention, and the recent trials demonstrating high efficacy of lenacapavir for HIV prevention have renewed excitement about LAIs. However, efficacy is not sufficient for impact. Consistent with prior reports [25–27, 30], our survey respondents endorsed numerous barriers to implementation that have substantially limited LAI prescribing and uptake in the US. Many of those barriers are driven by high drug pricing, impeding access particularly for uninsured and underinsured people and those living in states that have not expanded Medicaid. Although licensing agreements with generic manufacturers may help facilitate access to lenacapavir for HIV prevention and treatment in low-income countries [44], strategies are needed to ensure widespread access to existing and emerging LAI medications in other regions—including in the US, where the annual list price of lenacapavir for HIV treatment is $42 250. Successful implementation of LAIs also requires new workflows for drug procurement and delivery, which often cannot be accomplished without additional staffing, training, and resources. Upfront investments in personnel and other resources, such as integrated electronic health record tools, are necessary and should be supported by funders. Ending the HIV epidemic in the US will require a multisector commitment—including policy changes by health insurers, drug manufacturers, and federal and state governments—to achieve broad and equitable access to LAIs for HIV treatment and prevention.
    TVDr. Tara Vijayan

    Dr. Tara Vijayan

    Infectious Disease · General Infectious Disease
    University of California, Los Angeles
    tarav